Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Alison R. Sehgal(UPMC Hillman Cancer Center), Daanish Hoda(LDS Hospital), Peter A. Riedell(University of Chicago Medical Center), Nilanjan Ghosh(Levine Cancer Institute), Mehdi Hamadani(Medical College of Wisconsin), Gerhard Hildebrandt(Markey Cancer Center), John E. Godwin(Providence Portland Medical Center), Patrick M. Reagan(University of Rochester Medical Center), Nina D. Wagner‐Johnston(Johns Hopkins Hospital), James Essell(Oncology Hematology Care), Rajneesh Nath(The University of Texas MD Anderson Cancer Center), Scott R. Solomon(Northside Hospital), Rebecca Champion(Norton Healthcare), Edward Licitra(CancerCare), Suzanne Fanning(Prisma Health), Neel K. Gupta(Cancer Genetics (United States)), Ronald L. Dubowy(Bristol-Myers Squibb (United States)), Aleco D’Andrea(Bristol-Myers Squibb (Switzerland)), Lei Wang(Bristol-Myers Squibb (United States)), K. OGASAWARA(Bristol-Myers Squibb (United States)), Jerill Thorpe(Bristol-Myers Squibb (United States)), Leo I. Gordon(Northwestern University)
Cited by 230
Abstract
Related Papers
No related papers found
Powered by citation graph analysis